92 results about "Cell necrosis" patented technology

A cell necrosis apparatus is described. The cell necrosis apparatus includes an identification and usage device capable of performing an encrypted handshake protocol with an energy source. The identification and usage device is capable of identifying the cell necrosis apparatus, to prevent the use of unauthorized devices with the energy source, as well as controlling and causing a record to be made of a usage of the cell necrosis apparatus.

An enhanced method and device are provided to treat atrial fibrillation or inhibit or reduce restenosis following angioplasty or stent placement. A balloon-tipped catheter is disposed in the area treated or opened through balloon angioplasty immediately following angioplasty. The balloon, which can have a dual balloon structure, may be delivered through a guiding catheter and over a guidewire already in place. A fluid such as a perfluorocarbon flows into the balloon to freeze the tissue adjacent the balloon, this cooling being associated with reduction of restenosis. A similar catheter may be used to reduce atrial fibrillation by inserting and inflating the balloon such that an exterior surface of the balloon contacts at least a partial circumference of the portion of the pulmonary vein adjacent the left atrium. In another embodiment, blood perfusion is performed simultaneously. In another embodiment, tissue contacted by the cryoablation catheter, undesired to be ablated, is protected against damage by a separate heating step.

A cell necrosis apparatus for delivering thermal microwave energy to a specific site in a body, including: a. a microwave generator, b. a coolant delivery system for delivering and circulating a quantity of cooled liquid coolant via inlet and return passageways, c. a probe including a probe handle and a probe body having a proximal portion coupled to the probe handle and a distal portion, d. a microwave antenna in the distal portion of the probe body for applying thermal microwave energy to a specific site in cell necrosis treatment, and e. a microwave transmission line extending from the microwave generator to and through the probe handle and to and through the probe body to the microwave antenna and electrically coupled thereto, where the inlet and return coolant flow passageways extend from the coolant delivery system to and through the probe handle and thence extend coaxially about the microwave transmission line and along the length thereof within the probe body, and extend coaxially about the antenna and long the length thereof within the probe body, and where a first of the inlet and return coolant flow passageways is radially outward of and immediately adjacent the microwave transmission line and the antenna within the probe body and the other of the inlet flow passageways is radially outward of the first flow passageway.

An enhanced method and device are provided to treat atrial fibrillation or inhibit or reduce restenosis following angioplasty or stent placement. A balloon-tipped catheter is disposed in the area treated or opened through balloon angioplasty immediately following angioplasty. The balloon, which can have a dual balloon structure, may be delivered through a guiding catheter and over a guidewire already in place. A fluid such as a perfluorocarbon flows into the balloon to freeze the tissue adjacent the balloon, this cooling being associated with reduction of restenosis. A similar catheter may be used to reduce atrial fibrillation by inserting and inflating the balloon such that an exterior surface of the balloon contacts at least a partial circumference of the portion of the pulmonary vein adjacent the left atrium. In another embodiment, blood perfusion is performed simultaneously. In another embodiment, tissue contacted by the cryoablation catheter, undesired to be ablated, is protected against damage by a separate heating step.

A system is provided for treating tumor tissue sites of a patient. At least first and second mono-polar electrodes are configured to be introduced at or near the tumor tissue site of the patient. A voltage pulse generator is coupled to the first and second mono-polar electrodes. The voltage pulse generator is configured to apply sufficient electrical pulses between the first and second mono-polar electrodes to induce electroporation of cells in the tumor tissue site, to create necrosis of cells of the tumor tissue site, but insufficient to create a thermal damaging effect to a majority of the tumor tissue site.

An enhanced method and device are provided to inhibit or reduce restenosis following angioplasty or stent placement. A porous balloon-tipped catheter is disposed in the area treated or opened through balloon angioplasty immediately following angioplasty. The balloon, which can have a dual balloon structure, may be delivered through a guiding catheter and over a guidewire already in place. A fluid such as a perfluorocarbon flows into the balloon to freeze the tissue adjacent the balloon, this cooling being associated with reduction of restenosis. A similar catheter may be used to reduce atrial fibrillation by inserting and inflating the porous balloon such that an exterior surface of the balloon, as well as a portion of the cold working fluid, from the microporosity contacts at least a partial circumference of the portion of the pulmonary vein adjacent the left atrium.

A system for treating benign prostate hyperplasia (BPH) of a prostate. At least first and second mono-polar electrodes are configured to be introduced at or near a BPH tissue site of the prostate gland of the patient. A voltage pulse generator is coupled to the first and second mono-polar electrodes. The voltage pulse generator is configured to apply sufficient electrical pulses between the first and second mono-polar electrodes to induce electroporation of cells in the BPH tissue site, to create necrosis of cells of the BPH tissue site, but insufficient to create a thermal damaging effect to a majority of the BPH tissue site.

The present invention relates to pharmaceutically acceptable salts of an amide substituted indazole which are inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), previously known as poly(ADP-ribose)synthase and poly(ADP-ribosyl) transferase. The compounds of the present invention are useful as mono-therapies in tumors with specific defects in DNA-repair pathways and as enhancers of certain DNA-damaging agents such as anticancer agents and radiotherapy. Further, the compounds of the present invention are useful for reducing cell necrosis (in stroke and myocardial infarction), down regulating inflammation and tissue injury, treating retroviral infections and protecting against the toxicity of chemotherapy.

Described are methods and compositions that inhibit IL-1 signalling for the treatment of acute inflammatory response to cell necrosis, and the attendant collateral tissue damage.

The present invention is directed to a method and system for less invasive surgical procedures on animals. In accordance with various embodiments, electromagnetic energy is applied in a controlled application and projected into the tissue of an animal. The controlled application of the electromagnetic energy heats the targeted tissue causing cell necrosis, collagen shrinkage or scar tissue production, often without requiring a surgical incision.

The present invention relates to a combination of cell necrosis inhibitor and lithium, process for the preparation of the combination, pharmaceutical formulation containing the combination and use of the combination by either concomitant or sequential administration for improvement of treatment of neuronal death or neurological dysfunction. The combination of the present invention shows a synergic effect and thus is useful for treating neurological diseases, such as amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke, traumatic brain injury or spinal cord injury; and for treating ocular diseases such as glaucoma, diabetic retinopathy or macular degeneration.

A method and system for tumor ablation planning and guidance based on a patient-specific model of liver tumor ablation is disclosed. A patient-specific anatomical model of the liver and circulatory system of the liver is estimated from 3D medical image data of a patient. Blood flow in the liver and the circulatory system of the liver is simulated based on the patient-specific anatomical model. Heat diffusion due to ablation is simulated based on a virtual ablation probe position and the simulated blood flow in the liver and the venous system of the liver. Cellular necrosis in the liver is simulated based on the simulated heat diffusion. A visualization of a simulated necrosis region is generated and displayed to the user for decision making and optimal therapy planning and guidance.

The present invention features compounds, pharmaceutical compositions, and methods for treating trauma, ischemia, stroke, degenerative diseases associated with cellular necrosis, and other conditions. Screening assays for identifying compounds useful for treating these conditions are also described.

The present invention relates to 2-hydroxy-alkylamino-benzoic acid derivatives and to a combination of cell necrosis inhibitor and lithium, process for the preparation of the derivatives or the combination, pharmaceutical formulation containing the derivatives or the combination, and use of the derivatives or the combination by either concomitant or sequential administration for improvement of treatment of neuronal death or neurological dysfunction. The derivatives and the combination of the present invention are useful for treating neurological diseases, such as amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), spinal muscular atrophy, Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke, traumatic brain injury or spinal cord injury; and for treating ocular diseases such as glaucoma, diabetic retinopathy or macular degeneration.

The present invention relates to pharmaceutically acceptable salts of an amide substituted indazole which are inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), previously known as poly(ADP-ribose)synthase and poly(ADP-ribosyl) transferase. The compounds of the present invention are useful as mono-therapies in tumors with specific defects in DNA-repair pathways and as enhancers of certain DNA-damaging agents such as anticancer agents and radiotherapy. Further, the compounds of the present invention are useful for reducing cell necrosis (in stroke and myocardial infarction), down regulating inflammation and tissue injury, treating retroviral infections and protecting against the toxicity of chemotherapy.

The present invention relates to a pH sensitive particle, a method of preparation thereof, and a use thereof. More particularly, the invention provides a pH sensitive metal nanoparticle and its use for medical treatment utilizing cell necrosis during photothermal therapy. The pH sensitive metal nanoparticle based on this invention consists of a pH sensitive ligand compound whose charge changes depending on the pH of the metal nanoparticle. The particle can be collected in cells, such as cancer cells which present an abnormal pH environment. The pH sensitive metal nanoparticle based on this invention can induce cell death through a photothermal procedure after aggregation. Therefore, the invention enables medical treatment using cell necrosis for e.g. cancer treatment.

A method and system for interactive patient-specific simulation of liver tumor ablation is disclosed. A patient-specific anatomical model of the liver and circulatory system of the liver is estimated from 3D medical image data of a patient. A computational domain is generated from the patient-specific anatomical model of the liver. Blood flow in the liver and the circulatory system of the liver is simulated based on the patient-specific anatomical model. Heat diffusion due to ablation is simulated based on a virtual ablation probe position and the simulated blood flow in the liver and the circulatory system of the liver by solving a bio-heat equation for each node on the level-set representation using a Lattice-Boltzmann method (LBM) implementation. Cellular necrosis in the liver is computed based on the simulated heat diffusion. Visualizations of a computed necrosis region and temperature maps of the liver are generated. A user input is interactively received to modify the position of the virtual ablation probe, the heat diffusion and cellular necrosis is re-simulated based on the user input, and the visualizations of the computed necrosis region and the temperature maps are updated.

The invention relates to application of colchicin in preparing drugs, in particular to application of colchicin in pharmacotherapy of cholestatic liver disease, the application of colchicin in preparing a cholestatic liver disease drug, and the application of colchicin in preparing the drug for treating gestation intrahepatic cholestasis syndrome, inner primary cirrhose biliaire, primary sclerosing cholangitis severe jaundice or immunity jaundice cholestatic liver disease. The colchicin can effectively lower liver injury and cholestasis caused by cholestatic liver disease, i.e. the colchicin can effectively treat cholestatic liver disease. The colchicin can effectively lighten hepatic cell necrosis, inflammatory cell infiltration and bile capillary hyperplasia caused by cholestasis. The colchicin can effectively increase bile acid, bilirubin and expression of phospholipid transporters BSEP, MRP2 and MDR3 in a bile duct, accelerates excretion of bile acid, bilirubin and phospholipid deposited in the body and reduces liver damage.

The invention provides a cell necrosis inhibitor, and a preparation method and application thereof. Particularly, the invention provides an inhibitor for inhibiting cell necrosis and / or human receptorinteracting protein 1 kinase (RIP1). The inhibitor has a structure shown as in a following formula I. The compound and a composition comprising the compound are useful in the prevention and / or treatment of diseases involving cell death and / or inflammation.

The invention discloses MLKL protein and an application of the MLKL protein as a target point of a cell necrosis inhibitor. The invention provides the protein represented by the following: (a) the protein comprises the amino acid sequence represented by the sequence 1; (b) the protein comprises the amino acid sequence represented by the sequence 13; (c) the protein is obtained through mutation of threonine on site 357 of the N terminal of the sequence 13 into alanine; (D) the protein is obtained through mutation of serine on the site 358 of the N terminal of the sequence 13 into alanine; (E) the protein comprises the amino acid sequence from the site 179 of the N terminal of the sequence 1 to the site 471 of the N terminal of the sequence 1. The protein is combined with RIP3 protein to provide an apoptosis effect, such that the protein can be used as the target point of anti-apoptosis drugs, and used for screening and developing the anti-apoptosis drugs. The invention further provides compounds for inhibitions of the nucleic acid expressed by the gene and the protein, wherein the compounds can be used as products for inhibitions of the apoptosis. The MLKL protein of the present invention provides important values for medical research and drug development.

Provided is a biomarker that enables easy and rapid detection of oxidative stress on a living organism and enables prevention of tissue damage or cell necrosis by drug administration, and which is a powerful marker for the study of toxicity and pharmacokinetics of various agents. Oxidative stress is determined by measuring blood concentration of ophthalmic acid, which is a substance that varies in blood depending on the variation of reduced glutathione (GSH) concentration in a biological sample with the use of an analyzer such as a capillary electrophoresis-mass spectrometer. Further, an anti-oxidative stress agent is screened by administering an anti-oxidative stress candidate agent to a non-human animal under oxidative stress conditions, measuring blood concentration of ophthalmic acid, and evaluating the degree of decrease in the ophthalmic acid concentration.

The present invention relates to 2-hydroxy-alkylamino-benzoic acid derivatives and to a combination of cell necrosis inhibitor and lithium, process for the preparation of the derivatives or the combination, pharmaceutical formulation containing the derivatives or the combination, and use of the derivatives or the combination by either concomitant or sequential administration for improvement of treatment of neuronal death or neurological dysfunction. The derivatives and the combination of the present invention are useful for treating neurological diseases, such as amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), spinal muscular atrophy, Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke, traumatic brain injury or spinal cord injury; and for treating ocular diseases such as glaucoma, diabetic retinopathy or macular degeneration.

Methods and compositions for modulating necrosis and for treating neurological and cardiovascular diseases are described. The inventors have shown that BNIP3 is involved in cell necrosis and cell death involved in cardiovascular and neurological diseases.

The invention which belongs to the technical field of gene engineering relates to a male-sterile gene TCL, a coded protein thereof, a promoter thereof, a plasmid thereof and a host cell thereof. The male-sterile gene TCL of the invention is a gene which codes the following protein of (a) or (b): (a) a protein which is composed of an amino acid sequence represented by SEQ ID NO:2; and (b): a protein which has the activity of influencing tapetal programmed cell death, is derived from (a), and is obtained through substituting, deleting or adding one or some amino acids. The invention also relates to the promoter with a base sequence represented by SEQ ID NO:3, the protein with the amino acid sequence represented by the SEQ ID NO:2, and the plasmid and the host cell of the gene with a base sequence represented by SEQ ID NO:1. The TCL gene of the present invention has the function of maintaining tapetal programmed cell death of the paddy rice anther,and the deletion of the gene function can cause tapetal cell necrosis and male sterility of the paddy rice.

The invention discloses application of adenosine and derivatives thereof in prevention and treatment of medicament-induced liver injury, relating to application of adenosine and derivatives thereof such as adenosine monophosphate, adenosine diphosphate and adenosine triphosphate in protection of acetaminophen-induced liver injury. A mouse model adopted in the application is an acetaminophen-induced mouse acute hepatic failure model, the dosage of the adenosine or derivatives thereof is 0.1 to 5mmol / kg, and the adenosine and derivatives thereof can reduce the activities of aspartate aminotransferase (AST) and alanine transaminase (ALT) in the medicament-induced liver injury, reduce the substantial cell necrosis area and improve the glutathione level so as to prevent and treat the acetaminophen-induced liver injury caused by liver toxic medicaments. Animal experiments prove that the adenosine and derivatives thereof have a significant effect on preventing and treating the medicament-induced liver injury, so the adenosine and derivatives thereof can be used for the preventing and treating processes of the medicament-induced liver injury, and a new method and means are provided for clinically treating the medicament-induced liver injury.

The invention discloses protein BxCDP1 of bursaphelenchus-xylophilus pathogen-associated molecular patterns and application thereof. The amino acid sequence of the protein BxCDP1 of the pathogen-associated molecular patterns (PAMPS) is shown in SEQID NO.2. From effectors secreted by bursaphelenchus xylophilus and the PAMP, the defensive responses of a host plant, namely, a pine tree, to bursaphelenchus xylophilus invasion are studied, the protein BxCDP1 of the pathogen-associated molecular patterns is obtained from the bursaphelenchus xylophilus, it is proven through experiments that the protein BxCDP1 can trigger cell necrosis of various plants including the host plant, has a certain broad spectrum in cell necrosis triggering, and stimulates the defensive response of the host plant. The BxCDP1 triggered cell necrosis depends on a co-receptor BAK1 of pattern recognition receptors, the BxCDP1 can stimulate the accumulation of nicotiana benthamiana ROS and up regulation of PTI Marker genes, and the immunoreaction of the nicotiana benthamiana is stimulated. It can be seen that the BxCDP1 is a PAMP secreted by the bursaphelenchus xylophilus, and has important theoretical and practicalsignificance for revealing the pathogenic mechanism of the bursaphelenchus xylophilus and improving the resistance of the pine tree to the bursaphelenchus xylophilus in a targeted mode.